Total lymphocyte count: a surrogate marker for predicting CD4+ count in enrolled process for antiretroviral therapy in resource-limited settings

J Med Assoc Thai. 2008 Oct;91(10):1514-7.

Abstract

Objective: The purpose of the present study was to evaluate the correlation between total lymphocyte count (TLC) and CD4+ count and TLC cut-off for predicting CD4+ count < 200 cells/mm3.

Material and method: The 176-naïve HIV-infected patients from the OPD Khon Kaen Hospital, were recruited for CD4+ count by flow cytometer and TLC by automated cell counter. All results were analyzed by STATA statistical software for sensitivity, specificity, PPV and NPV.

Results: From 176 patients, 61 (34.7%) had CD4+ > 200 cells/mm3 and 115 (65.3%) had CD4+ < 200 cells/mm3. The ROC curve between CD4+ count and TLC showed TLC < 1,800 cells/mm3 could predict CD4+ count < 200 cells/mm3 with 78.26% sensitivity, 73.77% specificity, 84.91% PPV, and 64.29% NPV. The sensitivity was further decreased and specificity was increased when TLC was lower than cut-off.

Conclusion: The presented finding indicates that the appropriated TLC for predicting CD4+ count. < 200 cells/mm3 was TLC < 1,800 cells/mm3. TLC can also be used as a surrogate marker for starting ARV therapy in resource limited setting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Anti-Retroviral Agents / therapeutic use
  • Biomarkers
  • CD4 Lymphocyte Count*
  • CD4-Positive T-Lymphocytes*
  • Flow Cytometry
  • HIV Infections / diagnosis*
  • HIV Infections / drug therapy
  • HIV Infections / physiopathology
  • Humans
  • ROC Curve
  • Sensitivity and Specificity

Substances

  • Anti-HIV Agents
  • Anti-Retroviral Agents
  • Biomarkers